hypertrophic cardiomyopathy 6
MeSH: C563436ORPHA: 1551 Treatment Available
Overview
hypertrophic cardiomyopathy that has material basis in heterozygous mutation in the gene encoding the gamma-2 regulatory subunit of AMP-activated protein kinase (PRKAG2)
Available Treatments (1)
| Drug | Form | Status | Countries | Lead Time |
|---|---|---|---|---|
| mavacamten Orphan | oral capsule, 2.5mg, 5mg, 10mg, 15mg | FDA Approved | 9 | 14d |
Classification & Codes
MeSH Code
C563436Orphanet Code
ORPHA:155hypertrophic cardiomyopathy 6
| MeSH | C563436 |
| Orphanet | ORPHA:155 |
| Treatments | 1 drug(s) |
| Status | published |
Treatment Summary
Factual Authority
Last Updated3/20/2026
Clinical DataHPO · Orphanet
Drug DataFDA · EMA · CDSCO